Macquarie Group LTD Summit Therapeutics Inc. Transaction History
Macquarie Group LTD
- $80.3 Billion
- Q1 2025
A detailed history of Macquarie Group LTD transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 109,713 shares of SMMT stock, worth $2.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,713
Previous 85,753
27.94%
Holding current value
$2.16 Million
Previous $1.53 Million
38.3%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$481 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$229 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$129 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$95.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.97B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...